Cristina Gasparetto MD

Associate Professor, Medicine, Duke University School of Medicine

2100 Erwin RdDurham, NC 27705
Phone+1 919-620-4467

Dr. Gasparetto is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gasparetto's full profile Already have an account?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1996 - 1999
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Sapienza University of RomeClass of 1986

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NC State Medical License 1997 - 2027
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
TERMINATED
PHASE1
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
COMPLETED
PHASE2
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
COMPLETED
PHASE2

Publications & Presentations

PubMed

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
Ajai Chari, Caitlin Costello, Amrita Krishnan, Krina Patel, Rahul Banerjee
American Journal of Hematology. 2026-07-01
Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.
Allison O Taylor, Joshua S Mercer, Claire I Bradbury, Samantha M Thomas, Edwin Alyea 3rd
Bone Marrow Transplantation. 2026-06-01
Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.
Matthew A Bergens, Matthew Braun, Ernaya J Johnson, Yan Li, Jamie S Myers
Bone Marrow Transplantation. 2026-06-01

Journal Articles

Selinexor plus Low-Dose Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Suzanne Lentzsch, Cristina Gasparetto, Blood

Abstracts/Posters

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect¬ MM R...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory ...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to Be Presented at the American Society of Hematology 2020 Annual MeetingNovember 4th, 2020
OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
Expert Highlights Early Promise of Selinexor in MyelomaFebruary 8th, 2018